Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to regimens that are both expensive and associated with toxic eff ects. A curative intervention will be needed to fully stop the epidemic. The failure to eradicate HIV infection during long-term antiretroviral therapy shows the intrinsic stability of the viral genome in latently infected CD4T cells and other cells, and possibly a sustained low-level viral replication. Heterogeneity in latently infected cell populations and homoeostatic proliferation of infected cells might aff ect the dynamics of virus production and persistence. Despite potent antiretroviral therapy, chronic immune activation, infl ammation, and immune dysfunction persist, and are likely to have important eff ects on the size and distribution of the viral reservoir. The inability of the immune system to recognise cells harbouring latent virus and to eliminate cells actively producing virus is the biggest challenge to fi nding a cure. We look at new approaches to unravelling the complex virus-host interactions that lead to persistent infection and latency, and discuss the rationale for combination of novel treatment strategies with available antiretroviral treatment options to cure HIV.
Introduction
Antiretroviral therapy (ART) is one of the major medical successes of the late 20th century. Eff ective ART results in indefi nite viral suppression, restored immune function, improved quality of life, the near normalisation of expected lifespan, and reduced viral transmission. Despite the inherent potency of ART to suppress virus replication, treatment approaches have limitations; ART does not eliminate viral reservoirs, and needs lifelong adherence to expensive regimens that have potential short-term and long-term toxic eff ects. In 2010, more than 34 million people were estimated to be living with HIV, an increase of 17% over the past 10 years, and the number is expected to increase. Will we have enough resources worldwide to provide treatment and monitoring to all who need them? Even for those with access to ART, individual adherence is a big drawback. Additionally, despite virus control, HIV-associated complications persist, including a higher than normal risk of cardiovascular disease, cancer, osteoporosis, and other end-organ diseases. This increased risk might be due to the toxic eff ects of treatment or the consequences of persistent infl ammation and immune dysfunction associated with HIV. Therefore, novel treatment approaches that eliminate persistent virus and do not need lifelong adherence to expensive and potentially toxic antiretroviral drugs are needed.
Two broadly defi ned categories of a cure for HIV infection exist-a functional cure and a sterilising cure. A functional cure is defi ned as host-mediated control of HIV replication, in the absence of ART. A functional cure suppresses viral replication for a pre-defi ned period of time (eg, 5 years) in the absence of treatment, restores and stabilises eff ective immune function, and decreases both HIV-induced infl ammation (which could increase the risk of AIDS or non-AIDS morbidity) and in those individuals that maintain stable low-level plasma viral loads, reduces the risk of virus transmission to others.
A functional cure is achieved spontaneously by a rare group of individuals who naturally control HIV replication without treatment (so-called elite controllers). These patients are charac terised by a favourable HLA profi le and potent HIV-specifi c CD8 T-cell responses that are associated with a low viral DNA reservoir. In 2010, a second group of patients who initiated ART during acute infection, and controlled HIV for several years after interruption of ART was identifi ed. 1 These so-called posttreatment controllers are very rare, and unlike elite controllers, do not show strong HIV-specifi c CD8 T cell responses or have protective HLA alleles. 2, 3 A sterilising cure needs the complete elimination of replication-competent virus. Complete elimination of virus was probably fi rst achieved after myeloablative chemotherapy, whole-body irradiation, and successful transplantation of haemopoietic stem cells from a CCR5 delta32 homozygous donor into an HIV-infected individual with acute myelogenous leukaemia (the so-called Berlin patient). 4, 5 In a recent report 6 from Boston, USA, two patients with relapsed Hodgkin's lymphoma treated with ART who received a CCR5+/+ haemopoietic stem-cell transplant, had un detectable pro-viral DNA and replicationcompetent HIV 8-17 months after trans plantation. These fi ndings suggest that ablative conditioning, immunosuppressive treatment, and post-transplant graft-versushost disease-all of which were common in the Berlin patient and the Boston cases-might cause substantial and perhaps curative reductions in the size of the reservoir. 6 To establish whether the Boston individuals were truly cured, ART will need to be interrupted. Eff orts to pursue both functional and sterilising cures are in progress. An eff ective cure might need a combination of approaches For example, attempts to eradicate the reservoir might not work unless the capacity of the immune system to clear and control the virus is enhanced.
HIV reservoirs: obstacles to cure Establishment and maintenance of HIV latency
The HIV reservoir is established during primary infection. Administration of ART in very early acute infection seems to result in a low post-treatment total, and integrated DNA and HIV RNA concentrations, suggesting that aggressive treatment can decrease the size of the viral reservoir. 1, [7] [8] [9] Although early treatment can substantially reduce the size of the total reservoir, a stable population of latently infected CD4 cells transits into the long-lived latent reservoir, and is unaff ected by early combination ART (cART). 10 Most HIV pro-viral DNA is detected in CD4 T lymphocytes in lymphoid tissue. 11, 12 In blood, most HIV DNA is found in central memory and transitional memory T cells, which maintain the reservoir because of their intrinsic capacity to persist through homoeostatic proliferation and renewal. 13 Other cellular reservoirs that might exist include naive CD4 T cells, monocytes and macrophages, astrocytes, and microglial cells.
14 During long-term eff ective ART, steady-state, lowlevel plasma HIV RNA is achieved, typically from less than one to three copies of RNA per mL. 15 Chronic production of HIV from a stable reservoir of long-lived infected cells (the so-called latent reservoir) is probably the main source of this persistent HIV. However, persistent low-level replication could also play a part, especially in tissues in which continuing persistent viral replication, despite ART, might be caused by cell-to-cell spread and insuffi cient drug penetrance in tissues. 16, 17 A prerequisite for the establishment of HIV latency is the integration of viral DNA into the host chromatin and epigenetic silencing of active viral transcription. Two models have been proposed to explain latent infection in memory cells. The pre-activation latency model relies on the idea that HIV can directly infect a subset of resting CD4 T cells. 18, 19 The post-activation latency model proposes that activated antigen-specifi c CD4 memory T cells become preferentially infected, but avoid cell death, and then revert to a resting state. 20 The number of resting CD4 T cells that become latently infected varies widely between individuals, and could be as few as 1 per million CD4 T cells.
The molecular mechanisms contributing to the silencing of HIV DNA are complex. 21 Infected cells with replication-competent pro-virus are transcriptionally silenced by corepressor complexes that contain histone deacetylases, histone methyltransferases, and heterochromatin proteins; active methylation of the long terminal repeat might also play a part. 22, 23 Epigenetic silencing of a pro-virus can be reversed by agents that mobilise chromatin remodelling complexes to replace repressive complexes poised at the viral long terminal repeat. 24 Signals delivered through the T cell receptor (TCR-CD3 complex , and CD28 co-stimulation can drive productive transcription, suggesting that physiological activation of memory CD4 T cells can lead to virus production in vivo. 25 Activated CD4 T cells are the most permissive target for HIV infection. How recently infected activated cells become long-lived latently infected resting memory cells is not fully understood. Many regulatory pathways designed to blunt the eff ect of cell activation are turned on during T-cell activation, including the upregulation of negative regulators of T cell activationeg, PD-1, CTLA-4, TIM-3, LAG3, CD160, and 2B4 cellsurface receptors. Cells expressing these receptors could be preferentially latently infected with HIV. In a crosssectional study of long-term treated individuals, PD-1-expressing cells were enriched with HIV DNA. 13 Drugs that interrupt the molecular pathways associated with these negative regulators could help clear the reservoir.
Novel strategies to cure HIV Treatment intensifi cation of ART
If persistent low-level replication of HIV or de-novo infection of new target cells continues during treatment, the addition of potent agents (so-called intensifi cation) to a stable regimen could help reduce reservoir size. In treatment-intensifi cation studies up to now, new classes of drugs such as the HIV integrase inhibitor raltegravir or the CCR5 inhibitor maraviroc have not reduced residual viraemia. 26 Some reports have shown that intensifi cation with an integrase inhibitor leads to transient accumulation of pre-integration episomal DNA (2-long terminal repeat circles), and simultaneous reductions in CD8 T cell activation markers, suggesting inhibition of low-level viral replication. 26, 27 Findings from another study showed that intensifi cation with raltegravir reduced concentrations of HIV RNA in the ileum, which is rich in infected target cells, and a potentially ideal environment to support cell-to-cell transfer of virus during ART. However, reduction in HIV-1 DNA or residual viraemia was not seen. 28 ART might be unable to fully penetrate all tissues. Persistence of HIV replication in tissues justifi es eff orts to optimise drug delivery to enhance penetration into cells in tissues that present drugs fail to reach, including the CNS and possibly lymphoid tissues. 29 Virus activity needs to be measured in lymphoid tissue and other organs such as the gut, reproductive organs, and the brain to better understand the limitations of ART intensifi cation and to eradicate residual virus production.
Gene therapy
The case of the Berlin patient generated widespread interest in cell-based curative interventions. Allogeneic transplantation with stem cells from very rare donors who are naturally resistant to HIV is not a feasible strategy; therefore, much interest is now focused on gene therapy to delete the virus from infected cells or to produce cells resistant to HIV infection. 30 Three classes of DNA-editing enzymes are being studied for safety and effi cacy to target HIV coreceptors and pro-viral sequences: zinc-fi nger nucleases, transcription activatorlike eff ector nucleases, and homing endonucleases. 31, 32 The targeted gene-therapy approach of blocking CCR5 (CCR5-zinc-fi nger nuclease knockout T cells) is under investigation in phase 1 clinical trials of adoptive transfer of ex-vivo expanded autologous T cells (table 1) . 33 Phase 1 studies have shown that these approaches are safe and feasible. Other gene-based treatments that target HIV viral proteins with either an anti-HIV ribozyme or antisense RNA oligonucleotide constructs have been shown to safely and feasibly reduce viral load in phase 1 and phase 2a clinical trials. 34 Additionally, CD4 aptamer-CCR5-siRNA chimeras have proven to be safe and effi cacious in the humanised mouse model. 35 Interventions that interfere with pre-integration steps in the viral-life cycle are promising, and are being assessed in phase 1 trials. 36 The safety and effi cacy of gene delivery to specifi c cells and tissues, and access to these treatments, are major challenges for these approaches in the eradication of HIV infection.
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A three-tiered approach to reverse latency and eliminate reservoirs
Step one is the reactivation of latent infectious pro-viral genomes. The goal of HIV-1 reactivation treatment is to purge cellular reservoirs by stimulation of the transcriptional activity of latent HIV-1 pro-virus in infected CD4+ T cells. This purge results in the production of virusproducing cells that either die from the direct cytopathic eff ects of the virus or are cleared by host mechanisms. Although complex molecular mechanisms regulate the expression of pro-virus in latently infected cells, one possible strategy is to trigger NF-κB activity, the main host transcription factor for HIV-1 replication. 38, 39 Initial attempts to reactivate virus in patients on ART with two known inducers of NF-κB, interleukin (IL) 2 or anti-CD3 monoclonal antibody (OKT3), were unsuccessful, and were associated with dose-dependent toxic eff ects. [40] [41] [42] Other candidate NF-κB activating agents eff ective at inducing virus transcription in in-vitro latency models include prostratin, tumour necrosis factor-α, and the transient NF-κB-activating agent HIV-reactivating factor. 43 Drugs that stimulate protein kinase C, the generation of reactive oxygen species, or autophagy can also activate the NF-κB pathway to induce virus replication. Bryostatin 1 induces the PKC-NF-κB pathway and can work with other drugs to remodel chromatin tran scriptional co-activator complexes in the cell, reactivate virus, and promote cellular apoptosis. 44, 45 However, the generalised activation of CD4 T cells is associated with a substanital risk of systemic induction of proinfl am matory cytokines. Advocacy for small-molecule drugs to specifi cally reverse the pathways involved in chromatin silencing coincided with the introduction of the idea of latency in the mid 1990s. 46 The inhibition of histone deacetylases is interesting because these molecules block HIV-DNA transcription by pre venting transcription factors from accessing the HIV promoter. Two candidate histone deacetylase inhibitors have already entered clinical trials (table 1) . Valproic acid, a weak non-toxic inhibitor, was the fi rst drug to be studied. Despite promising results in a pilot study, subsequent studies failed to fi nd any benefi t, and investigators have moved on to study more potent drugs. [47] [48] [49] Vorinostat has shown promising results in the reactivation of virus in in-vitro models of latency. 50 In a 2012 pilot study, 11 of 16 patients treated with ART showed potential susceptibility to vorinostat ex vivo. 50 Eight of these patients were then administered one dose of vorinostat and showed a marked increase in their expression of RNA levels compared with baseline.
Other clinical trials of vorinostat are in progress (table 1) . In 2012, the histone deacetylase inhibitor romidepsin (FK288) was shown to be 1000 times more potent than vorinostat in the induction of latent HIV, and induced HIV-RNA expression ex vivo in 12 of 13 patients with HIV on cART. 51 Panobinostat (LBH589), givinostat (ITF2357), and belinostat (PXD101) also showed greater potency than vorinostat in the reacti vation of virus in latently infected cell lines (table 2) . 68 Coordinated action of several epigenetic modifi cations might be needed to initiate viral transcription. Optimum reactivation of epigenetically silenced pro-virus DNA might need multidrug combinations including histone deacetylases, protein kinase C activators, and specifi c histone methyltransferase inhibitors. The combination of a histone deacetylase inhibitor with the H3K9 histone methyltransferase inhibitor BIX01294 reactivated latent virus better than either drug alone. 57, 69 The main priority is to discover new molecules that are safe and can act alone or synergise with other drugs to reactivate virus transcription with high effi ciency. For example, in 2012, three drugs approved by the US Food and Drug Administration (dactinomycin, aclarubicin, and cytarabine) were found to act as priming agents in combination with other reactivating molecules to increase the number of cells producing virus. 63 
Mechanism of action Activation

NF-κB-inducing agents
Anti-CD3/CD28 52 52 In a small pilot study, one dose of disulfi ram given daily for 2 weeks to patients on cART was well tolerated and led to a transient increase in plasma virus RNA in a subset of patients (table 1) . 70 Other potential drug targets maintain latency, including the immune checkpoint blockers-eg, PD-1, which is expressed on latently infected CD4 cells during HIV infection. These molecules present a major barrier to T-cell activation by inhibiting signals transmitted through the T-cell receptor. [71] [72] [73] In patients given ART, PD-1 expression remains elevated and correlates with the size of the latent reservoir and high concentrations of cellassociated RNA and pro-viral DNA. Therefore, blocking PD-1 or combinations of coinhibitory mol ecules could serve a dual role in the reactivation of latent virus in CD4 cells, and relieve a functional block on virus-specifi c CD8 memory T cells by enhancement of antigen-specifi c proliferation and eff ector-cell diff eren tiation. 76, 77 The cytokine IL7 is needed for homoeostatic proliferation and survival of naive and memory CD4 T cells expressing the IL-7 receptor. 78 In studies of patients on ART with low CD4 cell counts, IL7 reconstituted naive and central memory T cells, 79, 80 and induced transient viraemia in six of 26 patients in one investigation. 81 In another study, exogenous IL7 reactivated HIV replication in CD4 memory T cells from some HIV-infected donors in vitro when cells were stimulated in cocultures of peripheral blood mononuclear cells.
82 IL7 induces the proliferation of CD4 memory T cells carrying integrated viral DNA (including central memory and transitional memory T cells); however, the ability to reactivate virus replication with IL7 in ex-vivo cultures is highly variable. 83 On the basis of these fi ndings, IL7 as a reactivating intervention is being tested in combination with ART intensifi cation with raltegravir plus maraviroc to prevent proliferation or reseeding of the latent reservoir (ERAMUNE 01 study; table 1).
Step two is to target residual virus replication. Chronic infl ammation is a major contributory factor to HIV immune activation and disease pathogenesis. [84] [85] [86] The infl ammatory process seems to be most destructive in lymphoid tissues, leading to collagen deposition, fi brosis, and irreversible damage to the lymphoid in frastructure as a result of early recruitment of regulatory T cells and production of transforming growth factor β. 87, 88 Despite suppressive ART, abundant amounts of HIV proteins (eg, p24, p17, and gp120) persist on the surface of the follicular dendritic cell network, and possibly contribute to chronic immune activation. 41, [89] [90] [91] Proinfl ammatory cytokines and interferon α production result in increased frequency of activated CD4 T cells, which could contribute to persistent low-level viraemia, and prevent the healing of damaged gut and lymph nodes. 92, 93 Chronic infl ammation causes the persistent upregulation of coinhibitory receptors and impaired immune function on antigen-specifi c T cells, including those that are needed to clear HIV reservoirs. Drugs that prevent the negative eff ects of infl ammation on func tional immune responses (eg, inhibition of PD-1-PDL interactions, type I interferons, and IL6), and enable the positive eff ects (eg, increased innate and HIV-specifi c T-cell immunity) could prove to be important for an eff ective cure strategy.
Several anti-infl ammatory drugs are in hypothesistesting phase I and phase 2 clinical trials to fi nd out whether they can attenuate chronic infl ammatory responses along with immune responses needed to eradicate latent reservoirs. For example, expression of CD38 and PD-1 on total CD8 and Gag-specifi c CD8 T cells was reduced in untreated HIV-infected patients given a cyclo-oygenase-2 inhibitor. 94, 95 The peroxisome proliferator-activated receptor (PPAR-c) agonists are a promising class of anti-infl ammatory molecules that include pioglitazone and lefl unomide. These two drugs are well tolerated, are eff ective in the treatment of chronic infl ammation, 96 and might reduce comorbidities (metabolic syndrome, dyslipidaemias, and glucose intolerance) that have been associated with long-term ART in HIV-infected patients. 97 Although treatment with chloroquine or hydroxychloroquine sulphate can substantially reduce HLA-DR CD38 CD8 T cells, and Ki-67 expression in CD4 and CD8 T cells, 98, 99 these drugs failed to show effi cacy in meeting these endpoints in HIV asymptomatic ART-naive patients. 100 Other drugs are under investigation: methotrexate and mesalazine, which should reduce infl ammation in the gut mucosa where much of the virus resides; anti-fi brotic agents such as ACE inhibitors, which may restore immune function; and several drugs aimed at other microbial infections, which can cause chronic immune activation including drugs aimed at reducing translocation of gut microbes across the damaged mucosal surfaces of the gut. Whether these anti-infl ammatory agents will help decrease virus production and ultimately decrease viral reservoirs remains to be shown.
Step three is the enhancement of host-mediated clearance of residual virus. Findings of several studies have shown the importance of cellular immunity in the control of HIV reservoir size. HIV-1 Gag-specifi c CD8 T cells isolated from elite controllers, but not from patients given ART, were shown to kill autologous resting CD4 T cells in which the virus was reactivated with vorinostat. 101 Moreover, functional anti-viral CD8 T cells are associated with reduced size of the central memory CD4 T cell reservoir in patients controlling their virus without ART. 102 High-avidity multifunctional CD8 cytotoxic T lymphocytes that target vulnerable regions in Gag are especially important in limiting virus diversity and reservoirs in individuals infected with HIV who have protective HLA class I alleles. [102] [103] [104] Therapeutic vaccines could re-stimulate CD8 CTL to prevent or control virus relapses and reestablish latent infection in CD4 T cells after treatment interruptions. 64, 105, 106 A few therapeutic vaccine trials such as the Ad5 HIV-1 gag vaccine (ACTG A5197 NCT00080106), and infusions of dendritic cells pulsed with inactivated HIV particles have shown transient viral suppression after treatment interruption. 107, 108 Eramune-02 is testing whether a DNA prime, replication defective, recombinant adenovirus serotype-5 boost strategy, with the Vaccine Research Center's polyvalent HIV-Gag, Pol, Nef, and Env vaccine can reduce the viral reservoir in patients undergoing an antiretroviral-intensifi cation regimen (table 1) .
The type I interferon response is an essential innate mediator of the acute antiviral response and inducer of the CD8 CTL eff ector. A 2013 study found that pegylated interferon alfa-2A could suppress virus replication in patients whose immune function was partly restored by cART. 109 Adjuvants inducing the production of type 1 interferons by conventional dendritic cells, plasmacytoid dendritic cells, and nonhaemopoietic cells might drive the activation and diff erentiation of quiescent memory CD4 T cells to induce viral replication and to activate memory CD8 CTL antiviral responses. Push-pull strategies combining synergistic combinations of molecular adjuvants such as toll-like receptor ligands and costimulatory molecules while blocking negative regulatory molecules (eg, PD-1, CTLA-4, TIM-3, CD160, and 2B4), immunosuppressive cytokines, and T regulatory func tion might further optimise induction of CD8 T eff ector and eff ector memory cells. 108, [110] [111] [112] High-dose IL15 can skew diff erentiation of high levels of CD8 T eff ector memory cells.
113 IL15 was also shown to be four times more potent than IL7 in the induction of virus production in latently infected CD4 cells. 83 Therapeutic vaccines with the adjuvant IL15, in combination with blockage of coinhibitory molecules such as PD-1, might enhance the killing of infected cells and prevent the replenishment of latent reservoirs by reactivated virus.
• Identify virus-producing cells and the location of viral sanctuaries, and establish the mechanisms by which virus establishes and maintains latent infection.
• Develop standardised in-vitro latency models in primary memory CD4 cells to help screen and prioritise reactivating compounds and combinations.
• Harmonise continuing eff orts of diff erent laboratories to develop a high-throughput primary T-cell model of HIV latency to screen for novel antilatency compounds.
• Develop and implement robust monitoring methods to quantitate single-copy cell-associated HIV RNA and HIV DNA to measure HIV reservoir and the proportion of cells producing virus in response to treatment. Because most proviral DNA is replication incompetent, assays that can directly measure replication-competent HIV DNA and quantitate HIV DNA and RNA double-positive cells are needed.
• Develop non-human primate models of antiretroviraltreated simian immunodefi ciency virus infection, and do proof-of-concept studies testing the safety and effi cacy of reactivation strategies and immune-based treatments.
• Develop humanised mouse models of HIV infection to assess novel eradication approaches and combinatorial strategies.
• As in oncology, develop non-comparative phase 1 and phase 2 clinical studies to rapidly screen many clinical strategies to determine safety and effi cacy, and introduce a regulatory framework that allows fast implementation of small-scale (eg, 10-20 patients per group) proof-of-concept hypothesis-driven trials.
• Develop guidelines to select patient populations on the basis of the risk-benefi t ratio associated with the primary objective of the study-ie, sterilisation or functional cure.
• Develop consensus protocols to defi ne time-to-primaryendpoints and the follow-up period for secondary endpoints that quantify reduction in the HIV reservoir in blood and tissues, levels of infl ammatory biomarkers, and functional antigen-specifi c immune responses for advancement to phase 2 studies. A phase 2b or phase 3 approach will need analytical treatment interruption of antiretroviral therapy in responders, and the evaluation of HIV reservoirs in blood and tissues after treatment withdrawal.
• Develop a universal web-based database for meta-analyses and hierarchical modelling of multicentre trials and protocols that can help identify the best approaches.
• Prospectively involve the HIV community, funding agencies, and regulatory authorities to discuss the complex ethical considerations, with special regard to the design and fi nancial support of clinical studies in HIV-cure research.
• Prepare public opinion for this new phase of research and discovery, and thereby prevent high expectations in the short-term, and re-address the emphasis on prevention as the main available strategy to fi ght the HIV/AIDS epide mic.
Panel: A new look at the design of clinical studies
Conclusions
To achieve a cure for HIV, the eff orts of the global research community need to be coordinated and transparent in sharing both positive and negative clinical results (panel). The discovery of a cure is one of the major medical challenges of our time. This goal has rallied all sectors of the biomedical community-ie, public, private, academic, and community groups, and consultation has led to the elaboration of a document that describes a strategy leading to a cure. 14 Many challenges are associated with the identifi cation of combinatorial approaches that can eff ectively induce reactivation of the latent reservoirs and enhance specifi c immune responses to control virus replication and eliminate virus-infected cells. Additionally, ethical issues need to be addressed in strategies that reactivate virus infection in individuals who are successfully treated with ART. Findings of recent studies show that immediate or early treatment with ART after infection could minimise the size and complexity of the latent reservoir, and might lead to post-treatment control. These results should provide us with the optimism to move forward with therapeutic interventions aimed at the eradication of HIV infection. Presently, prevention and early initiation of ART is the best way to control the HIV pandemic.
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